Skip to main content

3 Result(s)

within Dajun Yang Remove this filter English Remove this filter Cancer Research Remove this filter Hematology Remove this filter

and

  1. Article

    Open Access

    Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

    Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu… in Journal of Hematology & Oncology (2023)

    Download PDF (547 KB) View Article

  2. Article

    Open Access

    Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

    Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu… in Journal of Hematology & Oncology (2022)

    Download PDF (554 KB) View Article

  3. Article

    Open Access

    Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

    BCR-ABL1T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. I...

    Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu… in Journal of Hematology & Oncology (2022)

    Download PDF (2433 KB) View Article